Home » Stocks » Bausch Health Companies

Bausch Health Companies, Inc. (BHC)

Stock Price: $18.05 USD -2.08 (-10.33%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $18.18 +0.13 (0.72%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 6.40B
Revenue (ttm) 8.60B
Net Income (ttm) -2.04B
Shares Out 354.73M
EPS (ttm) -5.76
PE Ratio n/a
Forward PE 4.23
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $18.05
Previous Close $20.13
Change ($) -2.08
Change (%) -10.33%
Day's Open 19.72
Day's Range 17.94 - 19.76
Day's Volume 9,941,766
52-Week Range 11.15 - 31.97

More Stats

Market Cap 6.40B
Enterprise Value 28.85B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 354.73M
Float 308.97M
EPS (basic) -5.8
EPS (diluted) -5.76
FCF / Share 2.53
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 14.04%
Payout Ratio n/a
Shares Short 19.05M
Short Ratio 5.04
Short % of Float 6.12%
Beta 1.22
PE Ratio n/a
Forward PE 4.23
P/FCF Ratio 7.12
PS Ratio 0.74
PB Ratio 9.01
Revenue 8.60B
Operating Income -526.00M
Net Income -2.04B
Free Cash Flow 899.00M
Net Cash -22.45B
Net Cash / Share -63.29
Gross Margin 72.71%
Operating Margin -6.12%
Profit Margin -25.20%
FCF Margin 10.46%
ROA 2.61%
ROE -105.74%
ROIC -2.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 10
Overweight 0
Hold 7
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$27.94*
(54.79% upside)
Low
14.0
Current: $18.05
High
64.0
Target: 27.94
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue8,6018,3808,7249,67410,4478,2065,7703,4802,4271,181
Revenue Growth2.64%-3.94%-9.82%-7.4%27.31%42.23%65.77%43.38%105.5%-
Gross Profit6,2516,0296,1767,0637,8625,9703,8652,5111,731775
Operating Income-203-2,384102-5661,5272,001-12279.70300-110
Net Income-1,788-4,1482,404-2,409-292881-866-116160-208
Shares Outstanding352351350347343335321305305196
Earnings Per Share-5.08-11.816.83-6.94-0.852.58-2.70-0.380.49-1.06
Operating Cash Flow1,5011,5012,2902,0872,2572,3121,042657640263
Capital Expenditures-278-235-336-291-303-471-185-181-386-101
Free Cash Flow1,2231,2661,9541,7961,9541,841857476255162
Cash & Equivalents3,244723797542597323600916170400
Total Debt25,89524,30525,44429,84631,08815,22917,36811,0166,6513,595
Net Cash / Debt-22,651-23,582-24,647-29,304-30,491-14,906-16,767-10,100-6,481-3,195
Assets33,86332,49237,49743,52948,96526,30527,97117,95013,10810,795
Liabilities32,72729,67731,55340,27142,93620,90322,73814,2339,1785,884
Book Value1,0632,7335,8493,1525,9105,2795,1193,7173,9304,911
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bausch Health Companies, Inc.
Country Canada
Employees 21,700
CEO Joseph C. Papa

Stock Information

Ticker Symbol BHC
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: BHC

Description

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.